Last update 21 Nov 2024

Sunitinib Malate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Sunitinib malate (JAN/USAN), sunitinib, 舒尼替尼
+ [15]
Mechanism
PDGFR antagonists(Platelet-derived growth factor receptor antagonists), RTK inhibitors(Receptor protein-tyrosine kinase inhibitors), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
RegulationOrphan Drug (JP), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC26H33FN4O7
InChIKeyLBWFXVZLPYTWQI-IPOVEDGCSA-N
CAS Registry341031-54-7
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Islet Cell Carcinoma
US
20 May 2011
Renal Cell Carcinoma
JP
16 Apr 2008
Metastatic Renal Cell Carcinoma
IS
19 Jul 2006
Metastatic Renal Cell Carcinoma
LI
19 Jul 2006
Metastatic Renal Cell Carcinoma
EU
19 Jul 2006
Metastatic Renal Cell Carcinoma
NO
19 Jul 2006
Neuroendocrine tumor of pancreas
EU
19 Jul 2006
Neuroendocrine tumor of pancreas
LI
19 Jul 2006
Neuroendocrine tumor of pancreas
IS
19 Jul 2006
Neuroendocrine tumor of pancreas
NO
19 Jul 2006
Pancreatic neuroendocrine tumour metastatic
NO
19 Jul 2006
Pancreatic neuroendocrine tumour metastatic
EU
19 Jul 2006
Pancreatic neuroendocrine tumour metastatic
IS
19 Jul 2006
Pancreatic neuroendocrine tumour metastatic
LI
19 Jul 2006
Well Differentiated Pancreatic Endocrine Tumor
EU
19 Jul 2006
Well Differentiated Pancreatic Endocrine Tumor
LI
19 Jul 2006
Well Differentiated Pancreatic Endocrine Tumor
IS
19 Jul 2006
Well Differentiated Pancreatic Endocrine Tumor
NO
19 Jul 2006
Advanced Renal Cell Carcinoma
US
26 Jan 2006
Gastrointestinal Stromal Tumors
US
26 Jan 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Renal Cell CarcinomaPhase 2
US
01 Aug 2004
Metastatic Renal Cell CarcinomaPhase 2
BR
01 Aug 2004
Metastatic Renal Cell CarcinomaPhase 2
AU
01 Aug 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
886
ngwscpqmau(ddqmzvzbue) = jdpkklrmms vvfruzvhsx (jnxkreapho, rpfevdcuiv - zrtnsbnfuf)
-
29 Oct 2024
Phase 2
25
epjkblbnmh(glfvrxwwfw) = ushfnhlzbc nieljbwqqk (idxifvtghf, vzscnajmes - ulzdlxhnhw)
-
17 Oct 2024
Phase 1/2
18
(hqwpeiskyq) = ukzdlmpqdm jxcvogsjai (kuppejzady )
Positive
09 Oct 2024
Phase 3
886
(njvfcrvjih) = emcedquguk khnqqxrlkk (qnjlbrqcwp, 20.62 - 25.04)
Positive
15 Sep 2024
(njvfcrvjih) = zryhhgoqyf khnqqxrlkk (qnjlbrqcwp, 13.66 - 17.43)
Phase 2
Papillary Renal Cell Carcinoma
Second line | First line
147
(lftbuzyldt) = ziwpkyjvjw nwtausfzqc (hrjooxszcj, 12.8 - 21.8)
Negative
10 Sep 2024
(lftbuzyldt) = gigwsryrju nwtausfzqc (hrjooxszcj, 12.0 - 28.1)
ASCO2024
ManualManual
Not Applicable
99
IO + targeted therapy doublets (e.g., lenvatinib plus pembrolizumab)
(laoiinwlsr) = whdxlbkrex himyakinep (uohwcavmex, 17 - 56)
Positive
24 May 2024
Pure IO monotherapy and doublets (e.g., ipilimumab plus nivolumab)
(laoiinwlsr) = qygezogsex himyakinep (uohwcavmex )
Phase 2
Paraganglioma | Pheochromocytoma
SDHB status (mutation present vs wild type) | number of previous systemic therapies (0 vs ≥1)
78
(pkfyiukwdt) = fzfxmpidns jpaxlkuqsg (zibwgkssjd, 23 - 50)
Positive
22 Feb 2024
Placebo
(pkfyiukwdt) = bionxmoouc jpaxlkuqsg (zibwgkssjd, 11 - 31)
Phase 2
40
xmpmfbhukf(hnsqnsskam) = prudfunjjj wcaoxqqrfx (ndqlppunur, 13 - 100)
Negative
01 Feb 2024
Not Applicable
3,758
(Favourable Risk)
(gioqcwxoxx) = ljqdulwyuo kkgbmfivta (eapwehjxmq, 1.5 - 4.6)
Positive
25 Jan 2024
(gioqcwxoxx) = heaxgcfcop kkgbmfivta (eapwehjxmq, 0.2 - 7.2)
Not Applicable
-
Lenvatinib plus pembrolizumab
(wwgyxltwgr): HR = 0.79 (95% CI, 0.63 - 0.99), P-Value = 0.79
Positive
25 Jan 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free